MedTrace Logo

Low Dose Epcoritamab Plus GemOx in R/R DLBCL

NCT07451652 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-04-01

No results posted yet for this study

Summary

In this study, researchers are looking to determine whether Gemcitabine/Oxaliplatin plus a lower dose of Epcoritamab (12 mg) works to treat subjects with relapsed/refractory diffuse large B-cell lymphoma, who are candidates to autologous stem cell transplantation.

Conditions

  • Relapsed/Refractory Diffuse Large B Cell Lymphoma

Interventions

DRUG

Epcoritamab

Subjects will receive 2 step up doses of Epcoritamab (0.16 mg and 0.8 mg) followed by 12 mg weekly, for a total of three 21-day cycles (8 applications)

DRUG

Gemcitabine (1000 mg/m2)

Subjects will receive gemcitabine 1000 mg/m2 on days 1 and 15 of the three 21-day cycles.

DRUG

Oxaliplatin

Subjects will receive oxaliplatin 100 mg/m2 on day 1 of three 21-day cycles.

Sponsors & Collaborators

  • Hospital Universitario Dr. Jose E. Gonzalez

    lead OTHER

Principal Investigators

  • Perla R Colunga-Pedraza, MD · Hospital Universitario "Dr. José Eleuterio González"

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-17
Primary Completion
2027-09-30
Completion
2027-09-30
FDA Drug
Yes

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07451652 on ClinicalTrials.gov